TABLE 2.
Base Case Model Results
| Outcome | Sotagliflozin add-on | Insulin monotherapy | Difference |
|---|---|---|---|
| LYs | 13.08 | 11.81 | 1.27 |
| 10-year utilization | |||
| No. of patients with dialysis | 99.35 | 102.41 | −3.06 |
| No. of patients with transplant | 30.59 | 32.35 | −1.76 |
| 30-year utilization | |||
| No. of patients with dialysis | 241.30 | 224.97 | 16.33 |
| No. of patients with transplant | 104.50 | 100.23 | 4.47 |
| QALYs | |||
| Pre-ESRD | 6.75 | 6.16 | 0.59 |
| ESRD | 0.99 | 0.93 | 0.06 |
| Adverse events | −0.04 | −0.02 | −0.02 |
| Transplant | 0.00 | 0.00 | 0.00 |
| Total | 7.70 | 7.07 | 0.63 |
| Cost | |||
| Pre-ESRD | $259,742 | $260,717 | −$975 |
| ESRD | $73,693 | $76,571 | −$2,878 |
| Pharmacy | $96,424 | $27,364 | $69,060 |
| Adverse events | $25,252 | $15,227 | $10,025 |
| Transplant | $29,563 | $31,881 | −$2,318 |
| Total | $484,674 | $411,760 | $72,914 |
| NMB | +$21,635 | ||
| ICER | $115,677 | ||
ESRD = end-stage renal disease; ICER = incremental cost-effectiveness ratio; LY = life-year; NMB = net monetary benefit; QALY = quality-adjusted life-year.